Clinical Trials Logo

Clinical Trial Summary

The study is designed to determine whether there are clinical features that can be used as biomarkers to predict whether underlying Alzheimer's pathology is the cause of a speech and language based dementia. The primary hypothesis is that the proportion of patients who test positive for beta-amyloid deposition will vary across different speech and language based dementias.


Clinical Trial Description

Speech and language based dementias (SLDs) (often referred to as primary progressive aphasias or PPA) are neurodegenerative diseases in which speech or language impairments are the most salient features of the disease and explain deficits in activities of daily living. Patients with SLDs may have poor grammar, prominent anomia, comprehension deficits, speech production and articulation problems, difficulty with repetition of words or sentences, word finding pauses, or a combination of all these features. The SLDs can be further divided into different subtypes. Up to 50% of patients with SLDs that go on to autopsy have shown Alzheimer type pathology where beta-amyloid deposition is observed; the rest have pathology consistent with frontotemporal lobar degeneration where beta-amyloid deposition is absent. Future disease modifying treatments that target beta-amyloid will most likely differ from treatments that do not target beta-amyloid. As a consequence, biomarkers are needed to differentiate patients with SLDs with and without beta-amyloid deposition.

Little research has been done to identify biomarkers that could differentiate patients with SLDs with and without beta-amyloid, mainly because the gold standard to identify the presence of beta-amyloid has been pathological examination, which does not always occur, and may not occur until more than 10 years after onset. The recent development of [N-methyl-11C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole also known as 11C Pittsburgh Compound B or PiB is a solution to this problem since PiB allows the in vivo detection of beta-amyloid. Unfortunately, PiB is very expensive.

The long term goal of our research is to develop a cost effective algorithmic approach to the evaluation and diagnosis of patients presenting with SLDs. The objective of the studies outlined in this proposal is to identify clinical, neuropsychological, or imaging biomarkers that are readily available, relatively inexpensive, and non-invasive that will allow the differentiation of patients with SLDs with and without beta-amyloid deposition. We will use PiB as an indicator of beta-amyloid pathology. Our proposal is predicated upon our strong preliminary data showing that clinical, neuropsychological and radiological features differ between patients with SLDs with and without beta-amyloid deposition. Our central hypothesis is that temporo-parietal lobe findings such as memory loss, visuospatial/perceptual impairment, parietal lobe atrophy on magnetic resonance imaging (MRI), and parietal lobe hypometabolism on [18-F]-fluoro-deoxy-glucose positron emission tomography (FDG-PET), will be associated with beta-amyloid deposition (PiB positive status). On-the-other hand, frontal lobe features, such as apraxia of speech and behavioral and executive dysfunction, as well as extrapyramidal features such as Parkinsonism, will be associated with absence of beta-amyloid deposition (PiB negative status). The rationale for examining these clinical-imaging relationships is that successful predictions will provide a solid scientific foundation for the ultimate development of a cost effective algorithm to guide the diagnosis of SLDs.

Patients found to be eligible and willing to enroll in this study will be asked to undergo a Neurologic Examination, a Speech Pathology Consultation, Neuropsychometric testing, an MRI scan, an FDG PET scan and a PiB PET scan of the brain. This will be done over a period of two days at the Mayo Clinic in Rochester, MN. ;


Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT01623284
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase Phase 1
Start date March 2010
Completion date January 2015

See also
  Status Clinical Trial Phase
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Recruiting NCT03929432 - Treatment Outcomes With tDCS in Post-Stroke Aphasia N/A
Completed NCT03662295 - Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
Completed NCT03679637 - Tablet-based Aphasia Therapy in the Acute Phase After Stroke N/A
Completed NCT03550092 - Analysis of Brain Activity to Uncover Brain-behavior Relationships Related to Therapy Outcomes in Aphasia N/A
Completed NCT03228264 - A Trial Investigating Telerehabilitation as an add-on to Face-to-face Speech and Language Therapy in Post-stroke Aphasia. N/A
Suspended NCT04290988 - Circuitry Assessment and Reinforcement Training Effects on Recovery N/A
Recruiting NCT05969548 - pBFS-guided cTBS at Different Doses for Aphasia After Stroke N/A
Recruiting NCT04138940 - Modulating Intensity and Dosage of Aphasia Scripts N/A
Terminated NCT02249819 - Evaluating Anodal tDCS Preceding Aphasia Therapy Phase 1/Phase 2
Completed NCT01654029 - Patient Centred Communication Intervention N/A
Completed NCT00843427 - fMRI of Language Recovery Following Stroke in Adults N/A
Active, not recruiting NCT00227461 - Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients. Phase 1
Completed NCT03773419 - Improving Electronic Written Communication in Aphasia N/A
Not yet recruiting NCT04142866 - Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia N/A
Suspended NCT04048668 - tDCS to Treat Subacute Aphasia N/A
Recruiting NCT04081207 - Using Augmentative & Alternative Communication to Promote Language Recovery for People With Post-Stroke Aphasia N/A
Completed NCT02226796 - Transcranial Direct Stimulation (tDCS) and Behavioral Intervention in Aphasia N/A
Completed NCT01163461 - Phonomotor Treatment of Word Retrieval Deficits in Individuals With Aphasia N/A